TACSTD2 and head and neck squamous cell carcinoma: In prior work, we identified an inhibitor of ErbB3 activation, the transmembrane protein, Trop229 and showed that Trop2 depletion in HNSCC cell line xenografts predicted hypersensitivity to antibody-mediated ErbB3 inhibition.